What question did this study set out to answer?

To evaluate the efficacy of nivolumab and ipilimumab in patients with melanoma and untreated brain metastases.

August 22, 2018Open Access

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Key Points

To evaluate the efficacy of nivolumab and ipilimumab in patients with melanoma and untreated brain metastases.
Utilized a randomized trial design (CheckMate 204, NCT02320058).
Evaluated effects on patients with melanoma and untreated brain metastases.
Measured both intracranial and extracranial responses.
Nivolumab plus ipilimumab showed clinically meaningful intracranial efficacy.
Intracranial activity correlated with extracranial responses.

Abstract

Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases. (Funded by Bristol-Myers Squibb and the National Cancer Institute; CheckMate 204 ClinicalTrials.gov number, NCT02320058 .).

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper

Cite This Study

Tawbi et al. (Wed,) studied this question.

synapsesocial.com/papers/69dcd9bfd111c0385b359697 https://doi.org/https://doi.org/10.1056/nejmoa1805453

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper